Talazoparib plus enzalutamide shows improvement in PFS over SOC in first-line HRR mCRPC

TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPCSee more

Implications of the FDA Approval of Combination Talazoparib & Enzalutamide TherapySee more

TALAPRO-2 Study Design for 1L in mCRPC Patients - NOW FDA Approved | #oncology #cancer #2023See more

mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and TalazoparibSee more

TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPCSee more

TALAPRO-2: exploratory analyses of HRR gene subgroups in mCRPCSee more

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPCSee more

TALAPRO-2 Study of Talazoparib/Enzalutamide in Prostate Cancer: Stephen Freedland and Neeraj AgarwalSee more

TALAPRO-2: Phase 3 Results of Talazoparib Plus Enzalutamide for mCRPCSee more

Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset AnalysesSee more

Drs. Fizazi, Wallis on Updated Data from TALAPRO-2See more

STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RPSee more

Olaparib plus abiraterone for mCRPC: are biomarkers necessary?See more

Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPCSee more

Novel combination therapy regimen shows promising results for prostate cancerSee more

Enzalutamide in the non-metastatic setting for CRPCSee more

Assessing PARP inhibition and BRCA1/2 as a prognostic biomarker in mCRPCSee more

Updates from the CHEIRON study: docetaxel plus enzalutamide for mCRPCSee more

PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPCSee more